Let's review the charts and indicators.
Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.
A correction in EBS could soon set up an attractive opportunity.
This Friday several banks begin the unofficial kickoff of 'earnings season'.
The company's size and scale are nearly unmatched in its sector.
But know first that to really succeed in the sector, diversifying is key.
Aggressive traders could go long CVS at current levels.
Let's review the charts and indicators.
Let's review the charts and indicators.
Aggressive traders might want to look past any near-term price weakness and consider a small long position.